Insulet (PODD) EBIAT (2010 - 2026)

Insulet has reported EBIAT for 17 years, with the latest figure at $91.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIAT rose 157.34% year-over-year to $91.1 million; the trailing twelve-month figure through Mar 2026 stood at $302.8 million (down 24.71% YoY), and the FY2025 full-year result was $247.1 million, down 40.93% from the prior year.
• EBIAT for Q1 2026 stood at $91.1 million, down from $101.6 million in the prior quarter.
• The five-year high for EBIAT was $188.6 million in Q2 2024, with the low at -$35.0 million in Q2 2022.
• Historically, EBIAT has averaged $56.9 million across 5 years, with a median of $51.5 million in 2024.
• Annual changes were most pronounced in 2022 — EBIAT plunged 141.27% — and 2023, when it surged 1098.08%.
• Insulet's EBIAT stood at $17.0 million in 2022, then jumped by 507.65% to $103.3 million in 2023, then fell by 2.52% to $100.7 million in 2024, then advanced by 0.89% to $101.6 million in 2025, then dropped by 10.33% to $91.1 million in 2026.
• The last three EBIAT figures came in at $91.1 million (Q1 2026), $101.6 million (Q4 2025), and $87.6 million (Q3 2025), per Business Quant data.